Uncategorized

Sidewinder secures $137M to advance ‘precision’ ADCs

Published

on

Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version